Tags

Type your tag names separated by a space and hit enter

Identification of ampullary carcinoma mixed subtype using a panel of six antibodies and its clinical significance.
J Surg Oncol 2019; 119(3):295-302JS

Abstract

OBJECTIVES

To investigate the function of immunomarkers CK7, CK20, CK17, CDX2, MUC1, and MUC2 in the identification of primary ampullary carcinoma mixed subtype.

METHODS

Forty-two cases of primary ampullary carcinoma were performed by immunohistochemical studies. The correlation between the mixed subtype and the other two subtypes and patient survival data was analyzed using the SPSS 16.0 statistical software.

RESULTS

Among 42 cases, 12 (28.6%) cases were classified as mixed subtype, which showed variable expression patterns: 91.7% (11/12) for CK7, 83.3% (10/12) for CK20; 66.7% (8/12) for CK17, CDX2, and MUC1; and 50% (6/12) for MUC2. Ten (83.3%) mixed types coexpressed four or more immunomarkers. Eight (19%) intestinal subtypes mainly showed a positive expression of CK20, CDX2, and MUC2. Twenty-two (52.4%) pancreaticobiliary subtypes showed a positive expression of CK7, MUC1, and CK17. Stages III and IV diseases in mixed subtype (25%) and intestinal subtype (25%) were less than pancreaticobiliary subtype(63.6%) (p = 0.039). Follow-up data appeared to show a better survival rate for patients with mixed subtype than those with pancreaticobiliary subtypes.

CONCLUSION

Immunohistochemical staining provided a more reliable means of diagnosing mixed ampulla carcinoma. Accurate subtyping of ampullary carcinoma is clinically important to select effective chemotherapy regimens and to assess disease prognosis.

Authors+Show Affiliations

Department of Pathology, Peking University People's Hospital, Beijing, China.Department of Pathology, Peking University People's Hospital, Beijing, China.Department of Pathology, Peking University People's Hospital, Beijing, China.Department of Pathology, Peking University People's Hospital, Beijing, China.Pathology and Laboratory Medicine Department, University of California, Los Angeles, California.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30548547

Citation

Liu, Fangfang, et al. "Identification of Ampullary Carcinoma Mixed Subtype Using a Panel of Six Antibodies and Its Clinical Significance." Journal of Surgical Oncology, vol. 119, no. 3, 2019, pp. 295-302.
Liu F, Shen D, Ma Y, et al. Identification of ampullary carcinoma mixed subtype using a panel of six antibodies and its clinical significance. J Surg Oncol. 2019;119(3):295-302.
Liu, F., Shen, D., Ma, Y., Song, Q., & Wang, H. (2019). Identification of ampullary carcinoma mixed subtype using a panel of six antibodies and its clinical significance. Journal of Surgical Oncology, 119(3), pp. 295-302. doi:10.1002/jso.25311.
Liu F, et al. Identification of Ampullary Carcinoma Mixed Subtype Using a Panel of Six Antibodies and Its Clinical Significance. J Surg Oncol. 2019;119(3):295-302. PubMed PMID: 30548547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identification of ampullary carcinoma mixed subtype using a panel of six antibodies and its clinical significance. AU - Liu,Fangfang, AU - Shen,Danhua, AU - Ma,Yingteng, AU - Song,Qiujing, AU - Wang,Hanlin, Y1 - 2018/12/12/ PY - 2018/11/08/received PY - 2018/11/11/accepted PY - 2018/12/15/pubmed PY - 2018/12/15/medline PY - 2018/12/15/entrez KW - ampullary carcinoma KW - immunohistochemistry KW - immunomarker KW - mixed subtype KW - survival rate SP - 295 EP - 302 JF - Journal of surgical oncology JO - J Surg Oncol VL - 119 IS - 3 N2 - OBJECTIVES: To investigate the function of immunomarkers CK7, CK20, CK17, CDX2, MUC1, and MUC2 in the identification of primary ampullary carcinoma mixed subtype. METHODS: Forty-two cases of primary ampullary carcinoma were performed by immunohistochemical studies. The correlation between the mixed subtype and the other two subtypes and patient survival data was analyzed using the SPSS 16.0 statistical software. RESULTS: Among 42 cases, 12 (28.6%) cases were classified as mixed subtype, which showed variable expression patterns: 91.7% (11/12) for CK7, 83.3% (10/12) for CK20; 66.7% (8/12) for CK17, CDX2, and MUC1; and 50% (6/12) for MUC2. Ten (83.3%) mixed types coexpressed four or more immunomarkers. Eight (19%) intestinal subtypes mainly showed a positive expression of CK20, CDX2, and MUC2. Twenty-two (52.4%) pancreaticobiliary subtypes showed a positive expression of CK7, MUC1, and CK17. Stages III and IV diseases in mixed subtype (25%) and intestinal subtype (25%) were less than pancreaticobiliary subtype(63.6%) (p = 0.039). Follow-up data appeared to show a better survival rate for patients with mixed subtype than those with pancreaticobiliary subtypes. CONCLUSION: Immunohistochemical staining provided a more reliable means of diagnosing mixed ampulla carcinoma. Accurate subtyping of ampullary carcinoma is clinically important to select effective chemotherapy regimens and to assess disease prognosis. SN - 1096-9098 UR - https://www.unboundmedicine.com/medline/citation/30548547/Identification_of_ampullary_carcinoma_mixed_subtype_using_a_panel_of_six_antibodies_and_its_clinical_significance_ L2 - https://doi.org/10.1002/jso.25311 DB - PRIME DP - Unbound Medicine ER -